<code id='E3B135B9A2'></code><style id='E3B135B9A2'></style>
      • <acronym id='E3B135B9A2'></acronym>
      <center id='E3B135B9A2'><center id='E3B135B9A2'><tfoot id='E3B135B9A2'></tfoot></center><abbr id='E3B135B9A2'><dir id='E3B135B9A2'><tfoot id='E3B135B9A2'></tfoot><noframes id='E3B135B9A2'>
      • <optgroup id='E3B135B9A2'><strike id='E3B135B9A2'><sup id='E3B135B9A2'></sup></strike><code id='E3B135B9A2'></code></optgroup>
        5. <b id='E3B135B9A2'><label id='E3B135B9A2'><select id='E3B135B9A2'><dt id='E3B135B9A2'><span id='E3B135B9A2'></span></dt></select></label></b><u id='E3B135B9A2'></u>
          <i id='E3B135B9A2'><strike id='E3B135B9A2'><tt id='E3B135B9A2'><pre id='E3B135B9A2'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          focus 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          focus  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      -
 
browse：13519
                                  
                                    
          
                                    
            
          
 
          novavax photo illo
          JUSTIN TALLIS/AFP via Getty Images
          Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
          Hello, all. Damian here with an update on the plight of the other Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom.
          advertisement
          The need-to-know this morning
          • Ocular Therapeutics announced a shakeup of its senior management team and a $325 million private placement.
          • Amylyx Therapeutics said results from a closely followed Phase 3 study of its treatment for ALS could come before the start of the second quarter — earlier than previously expected.
          • Moderna earnings are here.
          Novavax’s money is going in the wrong direction
          The good news for Novavax is that it’s no longer facing a $700 million dispute with a global charity organization. The bad news is that settling that dispute will force the struggling company to pay out $400 million over the next five years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
           
 
 
          

                              
          
                                 Previous article：

                                
                                          Tori Bowie and the unacceptable rates of Black maternal death
                                
                            
          Next article：  
                                      
                                          State of the Union pitch: Bigger Medicare drug price negotiations
                                                                    
          

      
           
      
           
        
           
                                               
        
           focus 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          focus
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          entertainment
           
                                      
            
           
          
           
                                                          
             
          leisure time
           
                             
            
           
            
           

                                                         
             
          hotspot
           
               
              
            
           
            
           
                                                         
             
          focus
           
                             
      
           
 
     
           
     
           
      
          
              AresearcherworkinginthelabatCrineticsPharmaceuticalsinSanDiego.CourtesyCrineticsSANDIEGO—CrineticsPh
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP7228name